SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Redman12341/29/2025 9:16:13 AM
2 Recommendations

Recommended By
dorightbythem
Olecranon

  Read Replies (1) of 1229
 
Smart move. The most important thing was to get the Anktiva P3 Lung Cancer Trial started. BeiGene is a multinational oncology company that specializes in the development of drugs for cancer treatment, and most inportantly has offices in North America, Europe, South America, Asia and Australia. They can get the beds and patients. BMY sales reps will still be pounding the pavement with an approval for a Opdivo and Anktiva combo, but likely with a licensing deal. Same goes for Merck or anyone else with a checkpoint inhibitor. License out Anktiva to BMY, Merck, etc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News